BIO vs PRME · rev $651.0M vs rev $4.6M
BIO (BIO) versus Prime Medicine, Inc. Common Stock (PRME) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.
BIO currently screens at market cap $0. PRME currently screens at market cap $570.8M.
Not investment advice. Open the BIO and PRME stock pages for the full models.
Not investment advice.